

# Alleviating Effects of Long-QT Syndrome Type 2 by Allele-Specific Inhibition of the *KCNH2* Mutant Allele

Ronald Wilders

Department of Medical Biology, Amsterdam University Medical Centers,  
University of Amsterdam, Amsterdam, The Netherlands

## Abstract

*It has recently been demonstrated that the effects of long-QT syndrome type 1 can be alleviated by allele-specific 40–60% inhibition of mutant *KCNQ1*. We investigated whether the effects of long-QT syndrome type 2 (LQTS2) can similarly be alleviated by downregulation of mutant *KCNH2*, using the O’Hara–Rudy human ventricular cardiomyocyte model, updated with the rapid delayed rectifier potassium current ( $I_{Kr}$ ) Markov model from Li et al. (2017; PMID: 28202629).*

*If wild-type and mutant *KCNH2* proteins are equally expressed and co-assemble randomly, only 6.25% of the tetrameric  $I_{Kr}$  channels will completely consist of wild-type subunits. Inhibition of the mutant *KCNH2* allele by 60% decreases the overall number of  $I_{Kr}$  channels by 30%. However, if only  $I_{Kr}$  channels entirely built of wild-type subunits are conductive, as in severe LQTS2 mutations, the amount of conductive  $I_{Kr}$  channels increases almost three-fold, reducing the mutation-induced prolongation of the APD<sub>90</sub> at 1 Hz stimulation from 357 ms (+135%) to 236 ms (+89%). An even higher effect is obtained if the mutant *KCNH2* allele can be inhibited by as much as 80%.*

*We conclude that allele-specific inhibition of the *KCNH2* mutant allele in case of LQTS2 reduces the mutation-induced action potential prolongation and thus may alleviate the disease.*

## 1. Introduction

Long-QT syndrome type 1 (LQTS1) is caused by loss-of-function mutations in the *KCNQ1* gene, which encodes the pore-forming Kv7.1  $\alpha$ -subunit of the ion channel carrying the slow delayed rectifier potassium current ( $I_{Ks}$ ) [1]. Patients heterozygous for such a mutation co-assemble mutant and wild-type *KCNQ1*-encoded  $\alpha$ -subunits into tetrameric Kv7.1 potassium channels. Similarly, long-QT syndrome type 2 (LQTS2) patients are heterozygous for loss-of-function mutations in the *KCNH2* gene, which encodes the pore-forming Kv11.1  $\alpha$ -subunit of the ion channel carrying the rapid delayed rectifier potassium

current ( $I_{Kr}$ ) [2]. It has been shown that mutant and wild-type Kv channel subunits randomly co-assemble into functional tetramers [3]. Thus, these tetramers contain 0 to 4 mutant subunits according to a binomial distribution with parameters  $n = 5$  and  $p = 0.5$ , representing all possible combinations of a total of four wild-type or mutant subunits. This explains the common dominant-negative nature of LQTS1 and LQTS2 loss-of-function mutations in the *KCNQ1* (*KvLQT1*) and *KCNH2* (*HERG*) genes [4,5].

An example of the dominant-negative nature of LQTS2 mutations are the A561P, A561T, and A561V mutations at position 561 of the *KCNH2* gene. Bellocq et al. [6], who used African green monkey kidney cells (COS-7 cells) as their transfection system, observed an  $I_{Kr}$  tail amplitude of  $\approx 30\%$  in COS-7 cells co-injected with wild-type *KCNH2* cDNA plus A561P, A561T, or A561V *KCNH2* cDNA as compared to COS-7 cells injected with cDNA coding for wild-type *KCNH2*, suggesting that only channels with one mutant subunit max, constituting 5 of all 16 configurations possible in case of co-assembly of four wild-type or mutant subunits into a tetrameric ion channel (Fig. 1A), are conductive.

Recently, Cócera-Ortega et al. [7] demonstrated, both in vitro and in silico, that the effects of LQTS1 can be alleviated by allele-specific up to 60% inhibition of mutant *KCNQ1*. They investigated whether this allele-specific inhibition, by targeting a common single nucleotide polymorphism (SNP) on the mutant allele, can shift the balance of  $I_{Ks}$  channel subunits towards increased incorporation of the wild-type allele to alleviate the disease. Suppression of the mutant *KCNQ1* allele by 60% decreased the occurrence of arrhythmic events in human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs), whereas suppression of the wild-type allele increased the occurrence of arrhythmic events. Computer simulations revealed that 60% suppression of the mutant *KCNQ1* allele is particularly effective if only  $I_{Ks}$  channels without a mutant Kv7.1 subunit or with a single mutant Kv7.1 subunit are conductive and  $I_{Ks}$  channels with more mutant subunits are not.

Given the encouraging results by Cócera-Ortega et al. [7] regarding LQTS1, we questioned whether the effects of




Figure 1. (A) All 16 configurations possible in case of co-assembly of four wild-type or mutant subunits into a tetrameric ion channel. The black square and gray rectangle indicate channels containing exactly four or three wild-type subunits, respectively. (B) Fraction of rapid delayed rectifier potassium current ( $I_{Kr}$ ) channels with 0–4 wild-type (WT) subunits in case of equal expression of wild-type and mutant Kv11.1 subunits (WT 1.0 : mutant 1.0) and in case of 60% suppression of mutant Kv11.1 subunits (WT 1.0 : mutant 0.4), assuming random co-assembly of subunits into tetrameric channels.

LQTS2 can similarly be alleviated by allele-specific downregulation of mutant *KCNH2*. To this end, we carried out computer simulations with the O’Hara–Rudy human ventricular cardiomyocyte model [8], as updated with the Markov-type  $I_{Kr}$  formulation by Li et al. [9].

## 2. Methods

The allele-specific downregulation of mutant *KCNH2* was implemented in the CellML code [10] of the O’Hara–Rudy human ventricular cardiomyocyte model [8], as updated with the Markov-type  $I_{Kr}$  formulation by Li et al. [9], which is available at the CellML Model Repository and known as the “Comprehensive in vitro Proarrhythmia Assay (CiPA) 1.0 ORd model”, “ $I_{Kr}$ -dynamic ORd model”, or simply “ORd 2017 model”.

The CellML code was edited and run in the Cellular Open Resource (COR) environment by Garny et al. [11], version 0.9.31.1409. All simulations were run for a sufficiently long time to reach steady-state behaviour.

## 3. Results

First, we assessed the extreme case of a dominant-negative LQTS2 mutation in which only  $I_{Kr}$  channels built of four wild-type subunits are conductive. We assumed that wild-type and mutant Kv11.1 proteins are equally expressed in a 1:1 ratio and co-assemble randomly, thus creating a symmetrical binomial distribution of  $I_{Kr}$  channels built of 0–4 wild-type subunits (Fig. 1B, orange bars). Accordingly, only  $1/16^{\text{th}}$  (6.25%) of the  $I_{Kr}$  channels are conductive, reducing the fully-activated  $I_{Kr}$  conductance to only 6.25% of its control value. At 1 Hz stimulation, the action potential duration at 90% repolarization ( $APD_{90}$ ) increased by as much as 357 ms from its control value of 264 to 620 ms (+135%), as shown in Fig. 2A (arrow), as a result of the dramatic decrease in  $I_{Kr}$  (Fig. 2B).

Allele-specific inhibition of mutant *KCNH2* by 60%, thus creating a 1:0.4 ratio of wild-type and mutant subunits, results in skewing the binomial distribution of  $I_{Kr}$  channels towards channels containing 3 or 4 wild-type subunits (Fig. 1B; binomial distribution with parameters  $n = 5$  and  $p = 5/7$ ). The 60% inhibition makes that 26.0% of the  $I_{Kr}$  channels rather than only 6.25% are completely built of wild-type subunits, thus being conductive. This will result in a less dramatic decrease in  $I_{Kr}$ , but we have to keep in mind that the 60% inhibition also results in a 30% decrease in the total number of channels, so that the net effect is a reduction of the fully-activated  $I_{Kr}$  conductance to 18.2% of its control value. At 80% inhibition, the fully-activated  $I_{Kr}$  conductance amounts to 28.9% of its control value, representing that, at 80% inhibition, 48.2% of the  $I_{Kr}$  channels are completely built of wild-type subunits, whereas the total number of channels is decreased by 40%. The effects of 60% and 80% inhibition are shown in Fig. 2, A and B. At 60% inhibition,  $APD_{90}$  amounts to 500 ms, reducing its mutation-induced increase to 236 ms (+89%). At 80% inhibition, the mutation-induced action potential prolongation is further reduced to 177 ms (+67%). Because we assumed that only  $I_{Kr}$  channels built of four wild-type subunits are conductive, the maximum effect of the allele-specific inhibition of mutant *KCNH2* is obtained at 100% inhibition, at which the increase in  $APD_{90}$  amounts to 103 ms (+39%).

Next, we assessed the case of a more common dominant-negative LQTS2 mutation in which only  $I_{Kr}$  channels with one mutant subunit max are conductive. We started with the assumption that wild-type and mutant Kv11.1 proteins are equally expressed in a 1:1 ratio and co-assemble randomly, thus creating the symmetrical binomial distribution of  $I_{Kr}$  channels of Fig. 1B (orange bars). Under this assumption,  $5/16^{\text{th}}$  (31.25%) of the channels are conductive (Fig. 1A). Simulations with the fully-activated  $I_{Kr}$  conductance set to 31.25% of its control value show an increase in  $APD_{90}$  by 168 ms from its control value of 264 to 432 ms (+64%) and an  $I_{Kr}$  amplitude




Figure 2. Effects of dominant-negative LQTS2 mutations on the electrophysiology of a human ventricular cardiomyocyte. Membrane potential ( $V_m$ ) and associated rapid delayed rectifier potassium current ( $I_{Kr}$ ) of the O’Hara–Rudy human ventricular cardiomyocyte model [7] as updated with the Markov-type  $I_{Kr}$  formulation by Li et al. [8] (ORd 2017 model) at 1 Hz stimulation. (A)  $V_m$  and (B)  $I_{Kr}$  under control conditions and under the assumption that only  $I_{Kr}$  channels built of four wild-type subunits are conductive, at a 1:1 ratio of wild-type and mutant subunits (no inhibition of the mutant allele), at a 1:0.4 ratio (60% inhibition of the mutant allele), at a 1:0.2 ratio (80% inhibition of the mutant allele), and upon complete inhibition of the mutant allele (100% inhibition). (C)  $V_m$  and (D)  $I_{Kr}$  under control conditions and under the assumption that only  $I_{Kr}$  channels with one mutant subunit max are conductive, at a 1:1 ratio of wild-type and mutant subunits (no inhibition of the mutant allele), at a 1:0.4 ratio (60% inhibition of the mutant allele), at a 1:0.2 ratio (80% inhibition of the mutant allele), and upon complete inhibition of the mutant allele (100% inhibition). Horizontal arrows in the top panels indicate the increase in action potential duration at 90% repolarization in absence of inhibition of the mutant allele.

of approximately one-third of its control value (Fig. 2, C and D). The increase in  $APD_{90}$  is reduced to 111 ms (+42%) upon allele-specific inhibition of mutant *KCNH2* by 60%, associated with an increase in  $I_{Kr}$  amplitude from about one-third to nearly one-half of its control value (Fig. 2, C and D). The increase in  $APD_{90}$  is further reduced to 98 ms (+37%) upon 80% inhibition, associated with an increase in  $I_{Kr}$  amplitude to over one-half of its control value (Fig. 2, C and D).

Of note, unlike the extreme case in which only  $I_{Kr}$  channels built of four wild-type subunits are conductive (Fig. 2, A and B), the maximum effect of the allele-specific

inhibition of mutant *KCNH2* is not obtained at 100% inhibition. Whereas the increase in  $APD_{90}$  was reduced to 98 ms (+37%) upon 80% inhibition, it amounts to 103 ms (+39%) at 100% inhibition (Fig. 2, C and D). At this degree of inhibition, the  $V_m$  and  $I_{Kr}$  traces of Fig. 2, A and B, and those of Fig. 2, C and D, are identical.

#### 4. Conclusions

Inhibition of the mutant *KCNH2* allele in case of a dominant-negative LQTS2-causing mutation, e.g., by targeting a common single nucleotide polymorphism

(SNP) on the mutant allele, reduces the mutation-induced action potential prolongation and thus may alleviate the disease and reduce arrhythmias. Such inhibition may also turn out effective in case of short-QT syndrome type 1 patients, who are heterozygous for a gain-of-function mutation in the *KCNH2* gene.

## References

- [1] P. J. Schwartz, M. J. Ackerman, C. Antzelevitch, C. R. Bezzina, M. Borggrefe, B. F. Cuneo, and A. A. M. Wilde, "Inherited cardiac arrhythmias," *Nat. Rev. Dis. Primers*, vol. 6, no. 1, Jul. 2020, Art. no. 58.
- [2] C. T. January, Q. Gong, and Z. Zhou, "Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2," *J. Cardiovasc. Electrophysiol.*, vol. 11, no. 12, pp. 1413–1418, Dec. 2000.
- [3] C. Deutsch, "The courtship and marriage of  $K^+$  channel subunits," *Biol. Skr. Dan. Vid. Selsk.*, vol. 49, pp. 107–113, 1998.
- [4] F. Y. Shalaby, P. C. Levesque, W.-P. Yang, W. A. Little, M. L. Conder, T. Jenkins-West, and M. A. Blannar, "Dominant-negative *KvLQT1* mutations underlie the LQT1 form of long QT syndrome," *Circulation*, vol. 96, no. 6, pp. 1733–1736, Sep. 1997.
- [5] M. C. Sanguinetti, M. E. Curran, P. S. Spector, and M. T. Keating, "Spectrum of HERG  $K^+$ -channel dysfunction in an inherited cardiac arrhythmia (long QT syndrome)," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 93, no. 5, pp. 2208–2212, Mar. 1996.
- [6] C. Bellocq, R. Wilders, J.-J. Schott, B. Louérat-Oriou, P. Boisseau, H. Le Marec, D. Escande, and I. Baró, "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2," *Mol. Pharmacol.*, vol. 66, no. 5, pp. 1093–1102, Nov. 2004.
- [7] L. Cócera-Ortega, R. Wilders, S. C. Kamps, B. Fabrizi, I. Huber, I. van der Made, A. van den Bout, D. K. de Vries, L. Gepstein, A. O. Verkerk, Y. M. Pinto, and A.J. Tijssen, "shRNAs targeting a common *KCNQ1* variant could alleviate long-QT1 disease severity by inhibiting a mutant allele," *Int. J. Mol. Sci.*, vol. 23, no. 7, Apr. 2022, Art. no. 4053.
- [8] T. O'Hara, L. Virág, A. Varró, and Y. Rudy, "Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation," *PLoS Comput. Biol.*, vol. 7, no. 5, May 2011, Art. no. e1002061.
- [9] Z. Li, S. Dutta, J. Sheng, P. N. Tran, W. Wu, K. Chang, T. Mdluli, D. G. Strauss, and T. Colatsky, "Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-à-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology," *Circ. Arrhythm. Electrophysiol.*, vol. 10, no. 2, Feb. 2017, Art. no. e004628.
- [10] A. A. Cuellar, C. M. Lloyd, P. F. Nielsen, D. P. Bullivant, D. P. Nickerson, and P. J. Hunter, "An overview of CellML 1.1, a biological model description language," *Simulation*, vol. 79, no. 12, pp. 740–747, Dec. 2003.
- [11] A. Garny, P. Kohl, and D. Noble, "Cellular Open Resource (COR): a public CellML based environment for modelling biological function," *Int. J. Bifurcat. Chaos*, vol. 13, no. 12, pp. 3579–3590, Dec. 2003.

Address for correspondence:

Ronald Wilders, PhD  
Department of Medical Biology  
Amsterdam University Medical Centers  
University of Amsterdam  
Meibergdreef 15  
1105 AZ Amsterdam  
The Netherlands  
E-mail: r.wilders@amsterdamumc.nl